MedTrace Logo

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

NCT05938075 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in adults.

Conditions

Interventions

BIOLOGICAL

VXCO-100

Sterile suspension for injection

BIOLOGICAL

COVID-19 mRNA vaccine

Sterile suspension for injection

Sponsors & Collaborators

  • Medical Research Council, South Africa

    collaborator OTHER

  • Vaccine Company, Inc.

    lead INDUSTRY

Principal Investigators

  • Glenda Gray, MBChB, FC · Medical Research Council, South Africa

  • Ravindre Panchia, MBChB · Perinatal HIV Research Unit (PHRU)

  • Anusha Nana, BPharm · Perinatal HIV Research Unit (PHRU)

  • Mbalizethu Mntambo, MBChB · HIV and other Infectious Diseases Research Unit (HIDRU)

  • Samantha Siva, MMEDSc · HIV and other Infectious Diseases Research Unit (HIDRU)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-04
Primary Completion
2024-07-25
Completion
2024-07-25
FDA Drug
Yes

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05938075 on ClinicalTrials.gov